SCHEMBL25547732

SCHEMBL25547732

CC(C)OC1CC2(CCN(CC(=O)O)C2)C1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 4/20 0.35
ITGA2B P08514 4/20 0.35
CYP2D6 P10635 6/20 0.35
FFAR1 O14842 1/20 0.35
TSHR P16473 2/20 0.34
USP2 O75604 3/20 0.33
CYP3A4 P08684 3/20 0.33
CYP1A2 P05177 3/20 0.33
CYP2C9 P11712 1/20 0.33
FAAH O00519 1/20 0.32
MGLL Q99685 1/20 0.32
ABHD6 Q9BV23 1/20 0.32
ALOX15 P16050 1/20 0.32
HIF1A Q16665 1/20 0.31
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25543784 0.89 CYP2D6 (0.35) CYP2D6FFAR1TSHRUSP2CYP3A4
SCHEMBL23896280 0.84 ITGB3 (0.37) ITGB3ITGA2BCYP2D6FFAR1TSHR
SCHEMBL23968808 0.84 ITGB3 (0.37) ITGB3ITGA2BCYP2D6TSHRUSP2
SCHEMBL23906394 0.81 ITGB3 (0.37) ITGB3ITGA2BFFAR1HSD17B10
SCHEMBL25477017 0.80 ITGB3 (0.35) ITGB3ITGA2BFFAR1PDE4APDE4B
SCHEMBL25490289 0.79 CYP2D6 (0.33) CYP2D6TSHRUSP2CYP3A4CYP1A2
SCHEMBL23968807 0.79 ITGB3 (0.40) ITGB3ITGA2BCYP2D6TSHRCYP3A4
SCHEMBL23906369 0.77 ITGB3 (0.40) ITGB3ITGA2BCYP2D6TSHRCYP3A4
SCHEMBL25543789 0.76
SCHEMBL20793670 0.74 HRH3 (0.36) ITGB3ITGA2BCYP2D6TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 ITGB3 3371/4885ITGA2B 2614/4885CYP2D6 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.